Clinical trial
Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)
NCT04881916 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- December 1, 2021
- Completion date
- July 1, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic lymphoma kinase gene translocation, non-small cell lung cancer